Deerfield Management

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Curation Health, LLC offers a clinical decision support platform designed to facilitate the transition from fee-for-service to value-based care. Founded in 2018 and based in Annapolis, Maryland, the company provides a point-of-care solution that integrates with electronic health records to deliver actionable risk adjustment insights. This platform captures accurate clinical data before and after patient visits, ensuring comprehensive provider documentation. Curation Health's services enhance performance for various healthcare programs, including Medicare Advantage, MSSP, Medicaid risk programs, and quality initiatives based on standard measures. By leveraging clinical and quality rules, the platform aims to improve documentation processes and the overall value of patient care.

QMES, LLC is a privately held company specializing in the distribution of medical equipment and supplies. It serves hospitals, rehabilitation centers, skilled nursing facilities, and home patients across Pennsylvania, New Jersey, New York, Maryland, and Delaware. Founded in 2012 and based in Phoenixville, Pennsylvania, QMES provides a diverse range of products, including those for sleep and respiratory therapy, mobility aids, wound care, non-invasive ventilation, and nutritional support. Additionally, the company offers services such as respiratory therapy, wound care, nursing, and dietary consultations. To enhance customer convenience, QMES also provides online bill payment services, allowing users to manage and pay for their medical equipment expenses. The company is committed to addressing the unique challenges faced by patients, healthcare providers, and facilities during the transition from hospital to home care.

Dracen Pharmaceuticals, Inc. is a biotechnology company based in Baltimore, Maryland, founded in 2016. The company specializes in the discovery and development of anticancer therapies, focusing on novel glutamine antagonists. These innovative therapies aim to directly reduce tumor size and improve the tumor microenvironment, thereby enhancing the effectiveness of immuno-oncology treatments. Dracen's approach seeks to increase the number of patients who respond to cancer therapies and extend survival rates, particularly in cases where traditional immuno-oncology methods have been less effective. Through its commitment to advancing cancer treatment, Dracen Pharmaceuticals is dedicated to improving outcomes for cancer patients.

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

Advantia Health, LLC is a healthcare delivery company focused on providing comprehensive services to women and their families. Founded in 2014 and headquartered in Arlington, Virginia, Advantia Health offers a range of services including obstetrics, gynecology, primary care, and mental wellness, with additional locations in Virginia, Maryland, Illinois, and Missouri. The company emphasizes high-quality and efficient care through the use of technology and well-designed outpatient facilities. Advantia Health also provides telehealth services, allowing patients to connect with healthcare providers via a web and mobile application, ensuring timely access to the right care in the appropriate setting.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapy product candidates that utilize its proprietary NAV Technology Platform, which is based on adeno-associated virus (AAV) gene delivery. This platform aims to address genetic defects and enable cells to produce therapeutic proteins or antibodies to combat various diseases. The company's lead candidate, RGX-314, is currently undergoing Phase I/IIa clinical trials for wet age-related macular degeneration. Other notable product candidates include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia, all in various stages of clinical trials. Additionally, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has partnered with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Nuo Therapeutics is a biotechnology company that develops, sells, and licenses regenerative biological therapies to primarily address the areas of wound care, inflammation, and angiogenesis. The Company markets the AutoloGel System, a device for the production of platelet rich plasma gel derived from the patient's own blood. The AutoloGel System is cleared by the United States Food and Drug Administration for use on a variety of exuding wounds. Nuo Therapeutics is headquartered in Gaithersburg, Maryland.

MiddleBrook Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease.